Anti-Parkinson botanical Mucuna pruriens prevents levodopa induced plasmid and genomic DNA damage
- PMID: 17622977
- DOI: 10.1002/ptr.2219
Anti-Parkinson botanical Mucuna pruriens prevents levodopa induced plasmid and genomic DNA damage
Abstract
Levodopa is considered the 'gold standard' for the treatment of Parkinson's disease. However, a serious concern is dyskinesia and motor fluctuation that occurs after several years of use. In vitro experiments have shown that in the presence of divalent copper ions, levodopa may induce intense DNA damage. Mucuna pruriens cotyledon powder (MPCP) has shown anti-parkinson and neuroprotective effects in animal models of Parkinson's disease that is superior to synthetic levodopa. In the present study two different doses of MPCP protected both plasmid DNA and genomic DNA against levodopa and divalent copper-induced DNA strand scission and damage. It exhibited chelation of divalent copper ions in a dose-dependent manner. The copper chelating property may be one of the mechanisms by which MPCP exerts its protective effects on DNA.
Copyright (c) 2007 John Wiley & Sons, Ltd.
Similar articles
-
Antiparkinson drug--Mucuna pruriens shows antioxidant and metal chelating activity.Phytother Res. 2008 Jan;22(1):6-11. doi: 10.1002/ptr.2109. Phytother Res. 2008. PMID: 18064727
-
Neuroprotective effects of the antiparkinson drug Mucuna pruriens.Phytother Res. 2004 Sep;18(9):706-12. doi: 10.1002/ptr.1514. Phytother Res. 2004. PMID: 15478206
-
Effect of antiparkinson drug HP-200 (Mucuna pruriens) on the central monoaminergic neurotransmitters.Phytother Res. 2004 Feb;18(2):97-101. doi: 10.1002/ptr.1407. Phytother Res. 2004. PMID: 15022157
-
Management of Parkinson's disease in Ayurveda: Medicinal plants and adjuvant measures.J Ethnopharmacol. 2017 Feb 2;197:46-51. doi: 10.1016/j.jep.2016.08.020. Epub 2016 Aug 17. J Ethnopharmacol. 2017. PMID: 27544001 Review.
-
Mucuna pruriens to treat Parkinson's disease in low-income countries: Recommendations and practical guidelines from the farmer to clinical trials. Paving the way for future use in clinical practice.Parkinsonism Relat Disord. 2024 Jul;124:106983. doi: 10.1016/j.parkreldis.2024.106983. Epub 2024 May 8. Parkinsonism Relat Disord. 2024. PMID: 38797572 Review.
Cited by
-
A comprehensive review of natural compounds and their structure-activity relationship in Parkinson's disease: exploring potential mechanisms.Naunyn Schmiedebergs Arch Pharmacol. 2025 Mar;398(3):2229-2258. doi: 10.1007/s00210-024-03462-4. Epub 2024 Oct 11. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 39392484 Free PMC article. Review.
-
Mucuna pruriens in Parkinson's and in some other diseases: recent advancement and future prospective.3 Biotech. 2020 Dec;10(12):522. doi: 10.1007/s13205-020-02532-7. Epub 2020 Nov 10. 3 Biotech. 2020. PMID: 33194526 Free PMC article. Review.
-
Nutraceuticals in Parkinson's Disease.Neuromolecular Med. 2016 Sep;18(3):306-21. doi: 10.1007/s12017-016-8398-6. Epub 2016 May 4. Neuromolecular Med. 2016. PMID: 27147525 Free PMC article. Review.
-
L-Theanine Effectively Protects Against Copper-Facilitated Dopamine Oxidation: Implication for Relieving Dopamine Overflow-Associated Neurotoxicities.Mol Neurobiol. 2025 Apr;62(4):4993-5005. doi: 10.1007/s12035-024-04601-x. Epub 2024 Nov 5. Mol Neurobiol. 2025. PMID: 39499422
-
A blend of chlorophytum borivilianum and velvet bean increases serum growth hormone in exercise-trained men.Nutr Metab Insights. 2011 Oct 2;4:55-63. doi: 10.4137/NMI.S8127. eCollection 2011. Nutr Metab Insights. 2011. PMID: 23946662 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources